SGP
SpyGlass Pharma, Inc. Common Stock
SGP
Closed
$17.73
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. The firm is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
Key stats
Open
$18.00
Volume
103.72K
Market cap
$633.23M
Prev. close
$17.55
Impl / hst vl
-
Open interest
$0.00
$18.00
Day’s Range
$18.01
$17.60
52W Range
$30.56
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
-
Current ratio
38.00
Debt / Equity
-0.96
ROE
-
Gross margin
-
Income growth
-65.34%
FCF growth
45.78
Analysts estimates
Consensus rating
Strong buy
The average rating from top 5 analysts indicates that stock may significantly outperform the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$45.90
The top 6 analysts forecasts that 12-month price may increase by 158.88%, with a low of $37.37 and a high of $65.10
$37.37
Low
$45.90
Avg
$65.10
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$13.82M
Revenue
Net income
Previous EPS
-Estimate EPS
-$0.51
Actual EPS
Estimate EPS
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply